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This study was designed to test in vitro efficacy of 2 improved
hydrogen peroxide (HP) products against 3 standard HP products
and 1 quaternary ammonium compound. Improved HP is signifi-
cantly superior to standard HP at the same concentration and can
be used for disinfection of environmental surfaces or noncritical
patient care items.
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An improved hydrogen peroxide–based technology has been
introduced into health care for disinfection of noncritical
environmental surfaces and patient equipment1 and high-
level disinfection of semicritical equipment such as endo-
scopes.2-4 Improved hydrogen peroxide (HP) contains very
low levels of anionic and/or nonionic surfactants in an acidic
product, which act with HP to produce microbicidal activity.
This combination of ingredients speeds the antimicrobial ac-
tivity of hydrogen peroxide and cleaning efficiency.3,4 Im-
proved HP is considered safe for humans and equipment and
benign for the environment. In fact, improved HP has the
lowest Environmental Protection Agency (EPA) toxicity cat-
egory (ie, category IV) based on its oral, inhalation, and
dermal toxicity, which means it is practically nontoxic and
not an irritant.1,3,5 It is prepared and marketed by several
companies in various concentrations (eg, 0.5%–7%) and dif-
ferent products may use different terminology for these prod-
ucts such as “accelerated” or “activated.” Lower concentra-
tions (ie, 0.5%, 1.4%) are designed for the low-level
disinfection of noncritical environmental surfaces and patient
care objects while the higher concentrations (ie, 12%) can
be used as high-level disinfectants for semicritical medical
devices (eg, endoscopes).
The purpose of the study was to evaluate the antimicrobial
activity of new HP formulations designed for disinfection on
noncritical environmental surfaces and noncritical patient
care equipment with older standard HP formulations and a
quaternary ammonium compound (QUAT).
methods
Disinfectants Tested
We tested the following disinfectants: A456-II a QUAT (Eco-
lab) at 1 : 256; Clorox Healthcare Hydrogen Peroxide Cleaner
Disinfectant (Clorox), undiluted; hydrogen peroxide (Owens
and Minor) at undiluted (3.0%), 1.4%, and 0.5%; and Oxivir
TB (Johnson Diversey), undiluted.
Test Organisms
We tested 3 epidemiologically important pathogens: a com-
munity-acquired methicillin-resistant Staphylococcus aureus
strain (MRSA; USA300), vancomycin-resistant Enterococcus
(VRE; ATCC 51299), and multidrug-resistant (MDR) Aci-
netobacter baumannii (clinical strain).
Our test organism suspensions were prepared fresh daily
by plating each organism to sheep blood agar (SBA; Remel)
and incubating it at 37C for approximately 18 hours before
each run. Immediately before each run, 0.5 McFarland stan-
dard suspensions were prepared from these plates separately
for each organism in trypticase soy broth (TSB; Remel). To
simulate loading with organic material, fetal calf serum (Re-
mel) at a final concentration of 5% was added to the TSB.
Disinfectant Testing
The second tier of a quantitative carrier test, a standard of
ASTM International, was used to determine the bactericidal
activity of the formulations.6 In this test, stainless steel disks
(1-cm diameter # 0.7 mm thick; Muzeen and Blythe) were
contaminated with 10 mL of test suspension (103–106 colony-
forming units [CFUs] of the test organism). To detect low-
level antimicrobial activity (ie, !3-log10 reduction), a lower
inoculum (103 CFUs per carrier) was used when the disin-
fectant showed no bactericidal activity at the higher microbial
load. One disk each was placed, with contaminated side up,
at the bottom of a sterile 20-mL glass vial, covered with 50
mL of the test disinfectant and held for the desired contact
time (eg, 30 seconds, 1 minute) at room temperature (20
2C). We did not test times greater than 1 minute, which
may have been part of the label claim (eg, 10 minutes) because
these longer times are difficult to achieve in practice. At the
end of the contact time, the action of the disinfectant was
stopped by the addition of 9.95 mL neutralizer (0.85% NaCl
 0.1% Tween 80%  3% glycine [except for quaternary
ammonium compound used 1% sodium thiosulfate] at
pHp7.2–7.4). The contents of the vial were vortexed on high
for 1 minute to elute the inoculum from the surface of the
disks. The eluates and 3 washes of the vials with sterile saline
were passed through a membrane filter (Savur analytical fun-
nel containing a 0.22-mL filter; GE Water and Process Tech-
nologies). After the vial had been adequately rinsed, the sides
of the analytical funnel were rinsed with 40 mL of sterile
saline. Each filter was aseptically placed on the surface of SBA
and incubated at 37C for 48 hours. After 48 hours, the CFUs
were counted and the log10 reductions were calculated.
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table 1. Bactericidal Activity of Disinfectants (log10 Reduction) with a Contact Time of 30 Seconds or 1 Minute at 20C with and without
Fetal Calf Serum (FCS)
Organism
Oxivir TB
(0.5% H2O2) 0.5% H2O2
CHHPCD
(1.4% H2O2) 1.4% H2O2 3.0% H2O2
A456-II
(QUAT)
∼106 inoculum, contact time p 1 minute,
no 5% FCS
MRSA 16.62 ≤4.04 16.54 ≤4.04 ≤4.04 5.55
VRE 16.34 ≤3.61 16.13 ≤3.61 ≤3.61 4.58
MDR A. baumannii 16.76 ≤4.28 16.76 ≤4.28 ≤4.28 16.76
∼106 inoculum, contact time p 30 seconds,
no 5% FCS
MRSA 16.64 NT 16.64 NT ≤4.16 ≤4.16
VRE 16.28 NT 16.28 NT ≤3.80 ≤3.80
MDR A. baumannii 16.76 NT 16.76 NT ≤4.28 6.11
∼103 inoculum, contact time p 1 minute,
no 5% FCS
MRSA 13.71 ≤1.23 13.71 ≤1.23 ≤1.23 13.71
VRE 13.26 1.45 13.26 NT 1.40 13.26
MDR A. baumannii 13.53 ≤1.05 13.53 1.75 13.53 13.53
∼106 inoculum, contact time p 1 minute,
5% FCS present
MRSA 16.72 NT 16.72 NT ≤4.24 ≤4.24
VRE 16.26 NT 16.26 NT ≤3.78 ≤3.78
MDR A. baumannii 16.56 NT 16.56 NT ≤4.08 16.56
note. Individual mean values may have the same result because the same inoculums on the same day may have been run against multiple
disinfectants. If complete killing occurred, the minimum inactivation would equal the initial inoculum. Some results reported as “greater
than X” because complete killing of the inoculums occurred. A. baumannii, Acinetobacter baumannii; CHHPCD, Clorox Healthcare Hydrogen
Peroxide Cleaner Disinfectant; MDR, multidrug-resistant; MRSA, methicillin-resistant Staphylococcus aureus; NT, not tested; VRE, vanco-
mycin-resistant Enterococcus.
results
The bactericidal activities of the disinfectants tested are dis-
played in Table 1, and the statistical analysis is summarized
in Table 2. The 2 improved HP products had similar effec-
tiveness (eg, 16-log10 reduction within 30 seconds) against
the test organisms and were significantly superior to all 3
concentrations of HP. The improved HP products were su-
perior or similar to the QUAT tested. The standard HP prod-
ucts (ie, 3.0%, 1.4%, 0.5%) generally had similar bactericidal
activity. Finally, the QUAT was significantly superior or sim-
ilar to the standard HP products. These relationships held
true regardless of the presence or absence of fetal calf serum
and contact time.
discussion
There is excellent evidence in the scientific literature that
environmental contamination plays an important role in the
transmission of MRSA, VRE, Clostridium difficile, and Aci-
netobacter.7,8 These pathogens have been demonstrated to per-
sist in the environment for days (and in some cases, months)
to frequently contaminate the environmental surfaces in
rooms of colonized or infected patients, to transiently col-
onize the hands of healthcare personnel, to be transmitted
by healthcare personnel, and to cause outbreaks in which
environmental transmission was deemed to play a role. Fur-
thermore, admission to a room in which the previous patient
had been colonized or infected with MRSA, VRE, C. difficile,
or Acinetobacter has been shown to be a risk factor for the
newly admitted patient to develop colonization or infection.7,8
Although environmental contamination has been demon-
strated as an important component of patient-to-patient
transmission of these pathogens, the effectiveness of disin-
fectants to clean contaminated surfaces has not been com-
pletely assessed.
It has long been recommended in the United States that
environmental surfaces in patient rooms be cleaned and dis-
infected on a regular basis (eg, daily, 3 times per week), when
surfaces are visibly soiled, and after patient discharge.9 Disin-
fection is generally performed using a 1-step process with an
EPA-registered hospital disinfectant such as a QUAT. We com-
pared the bactericidal activity of a QUAT to 2 new, improved
HP products. The improved HP appeared to be superior or
similar to the QUAT tested. When the 2 improved HP products
were compared to 0.5%, 1.4%, and 3% HP formulations, the
improved HP-based environmental surface disinfectants
proved to be more effective (16-log10 reduction) and fast-acting
(30–60 seconds) microbicides in the presence of a soil load (to
simulate the presence of body fluids) than commercially avail-
able HP. Only 30–60-second contact time was studied because
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table 2. Comparative Efficacy of Improved Hydrogen Peroxide (HP), Standard HP, and a Quaternary Ammonium Compound
Oxivir TB 0.5% HP CHHPCD 1.4% HP 3.0% HP A456-II
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note. Mean log10 reductions, standard deviations, and 95% confidence intervals (CI) were calculated using replicate mea-
surements (2–4) for interproduct comparisons. CHHPCD, Clorox Healthcare Hydrogen Peroxide Cleaner Disinfectant; “1,”
nonoverlapping 95% CI (ie, means were statistically significant at P ! .05); “p,” overlapping 95% CI (ie, means P 1 .05).
Environmental Protection Agency (EPA) registration claim for A456-II is 10 minutes, CHHPCD is 30 seconds to 1 minute
(bactericidal), Oxivir TB is 1 minute (bactericidal), and standard HP had no EPA registration.
a Except against MDR-Acinetobacter baumannii (103 colony-forming units, contact 1 minute, no fetal calf serum).
longer contact times (eg, 10 minutes) are not achievable in
clinical practice. It appears, therefore, that the surfactants were
able to significantly increase the bactericidal activity of HP.
Additionally, the improved HP products have an EPA-regis-
tered contact time that is substantially less than most EPA-
registered low-level disinfectants.
Standard HP is among the oldest microbicides; however,
it is relatively unstable, somewhat slow acting, and has limited
antimicrobial activity. The stabilizers, surfactants, and other
excipients added to the improved HP formulations have ad-
dressed these weaknesses.1 Improved HP was also more ef-
fective than the tested quaternary ammonium compound and
standard HP. Thus, improved HP offers an option for non-
critical environmental surfaces and patient equipment, and
it addresses some concerns associated with some low-level
disinfectants (eg, toxicity, a contact time of 30–60 seconds).
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